Peptide record

TPDB92102

Dermaseptin - B2 Antibacterial Anticancer Antifungal Antiparasitic Toxicity modified_plain modified
33 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

Standard-residue backbone model; source-recorded chemical modifications are not verified in these coordinates.

TPDB92102
Dermaseptin - B2
Antibacterial Anticancer Antifungal Antiparasitic Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF AFP-GFuse Antifungipept CAFPdb dbAMP 3.0 ToxinPred 3.0
modified_plain
Yes
A 33-aa modified multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
C-terminal: Amidation
Sequence
GLWSKIKEVGKEAAKAAAKAAGKAALGAVSEAV-NH2
Physicochemical Analysis

Sequence-only estimates are not provided for modified or non-standard source notation. Reported molecular properties, when available, are retained below with their source records.

Chemical Descriptors
33 reviewed residue count
Amidation Activity
L Activity
Linear Activity
Free Activity
Antimicrobial Activity
Phyllomedusa bicolor Activity
Evidence Records 16 records
Evidence 1 Activity

Activity

GI50
GI50 > 10 µM
Anticancer
10 µM

Target

Brain Tumor
U-87-MG
Brain

Assay & Model

Crystal Violet assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2017

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation. dbAMP 3.0 classified as Anticancer under the disease-associated peptide function classes.
Evidence 2 Activity

Activity

GI50
GI50 > 10 µM
Anticancer
10 µM

Target

Brain Tumor
U-138-MG
Brain

Assay & Model

Crystal Violet assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2017
Evidence 3 Activity

Activity

GI50
GI50 > 10 µM
Anticancer
10 µM

Target

Brain Tumor
U-373-MG
Brain

Assay & Model

Crystal Violet assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2017
Evidence 4 Activity

Activity

GI50
GI50 > 10 µM
Anticancer
10 µM

Target

Breast Cancer
MDA-MB-231
Breast

Assay & Model

Crystal Violet assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2017
Evidence 5 Activity

Activity

GI50
GI50 > 10 µM
Anticancer
10 µM

Target

Breast Cancer
BT-474
Breast

Assay & Model

Crystal Violet assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2017
Evidence 6 Activity

Activity

GI50
GI50 > 10 µM
Anticancer
10 µM

Target

Breast Cancer
MDA-MB-453
Breast

Assay & Model

Crystal Violet assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2017
Evidence 7 Activity

Activity

GI50
GI50 > 10 µM
Anticancer
10 µM

Target

Pancreatic Cancer
PANC-1
Pancreas

Assay & Model

Crystal Violet assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2017
Evidence 8 Activity

Activity

GI50
GI50 = 2.31 ± 0.41 µM
Anticancer
2.31

Target

Pancreatic Cancer
BxPC-3
Pancreas

Assay & Model

Crystal Violet assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2017
Evidence 9 Activity

Activity

GI50
GI50 = 7.91 ± 1.40 µM
Anticancer
7.91

Target

Pancreatic Cancer
MIA PaCa-2
Pancreas

Assay & Model

Crystal Violet assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2017
Evidence 10 Activity

Activity

GI50
GI50 = 5.08 ± 0.72 µM
Anticancer
5.08

Target

Skin Cancer
HT-144
Skin

Assay & Model

Crystal Violet assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2017
Evidence 11 Activity

Activity

GI50
GI50 > 10 µM
Anticancer
10 µM

Target

Skin Cancer
SK-Mel-28
Skin

Assay & Model

Crystal Violet assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2017
Evidence 12 Activity

Activity

GI50
GI50 > 10 µM
Anticancer
10 µM

Target

Skin Cancer
A-375
Skin

Assay & Model

Crystal Violet assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2017
Evidence 13 Activity

Activity

GI50
GI50 = 0.71 ± 0.55 µM
Anticancer
0.71

Target

Prostate Cancer
DU-145
Prostate

Assay & Model

Crystal Violet assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2017
Evidence 14 Activity

Activity

GI50
GI50 = 2.17 ± 0.48 µM
Anticancer
2.17

Target

Prostate Cancer
PC-3
Prostate

Assay & Model

Crystal Violet assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2017
Evidence 15 Activity

Activity

GI50
GI50 = 2.65 ± 1.09 µM
Anticancer
2.65

Target

Prostate Cancer
LNCaP
Prostate

Assay & Model

Crystal Violet assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2017
Evidence 16 Activity

Activity

100% cytotoxicity at 2.5 µM
Anticancer

Target

Prostate Cancer
PC-3
Prostate

Assay & Model

LDH leakage assay
3-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2017